Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To evaluate whether the maximum standardized uptake value (SUVmax) from initial 18F-FDG PET/CT (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) scans could be a predictor of complete response and recurrence in patients with endometrial cancer who are undergoing fertility sparing management.

Methods: We conducted a retrospective review of patients who were diagnosed with endometrial cancer through biopsy and chose to undergo fertility sparing management using progestin at the Asan Medical Center, from January 2011 to December 2020. Of these, 113 patients who had an 18-FDG-PET/CT scan before starting treatment were included in our study. We measured SUVmax and examined its correlation with complete response and time to progression after achieving complete response to progestin therapy.

Results: Of 113 patients, 73 (64.6%) achieved a complete response through fertility sparing management. The receiver operating characteristic curve analysis revealed that the optimal cut-off value of SUVmax for predicting complete response was 6.2 (sensitivity 79.5%, specificity 57.5%, p=0.006). After analyzing recurrence in the 73 patients who achieved complete response, we found that patients with an SUVmax value >6.2 had a significantly shorter time to progression compared with those with a value <6.2. (p=0.04).

Conclusions: SUVmax values of PET-CT, along with other clinicopathological parameters, could be used to predict treatment response and recurrence risk in patients with stage I endometrial cancer undergoing fertility sparing management.

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2024-005441DOI Listing

Publication Analysis

Top Keywords

complete response
24
fertility sparing
16
endometrial cancer
12
sparing management
12
suvmax initial
8
initial 18f-fdg
8
18f-fdg pet/ct
8
undergoing fertility
8
recurrence patients
8
113 patients
8

Similar Publications

Objectives: Dental trauma is a frequent injury in contact sports such as handball an basketball. This study aimed to evaluate preventive measures in dental traumatology and assess the knowledge of medical teams in elite German handball and basketball.

Material And Methods: From March to June 2024, supervisors of 1st and 2nd German Bundesliga handball (HB) and basketball (BB) teams were invited via email to complete an online questionnaire (Socey Survey).

View Article and Find Full Text PDF

The anterior cruciate ligament (ACL) of the knee is commonly injured and can lead to joint instability. ACL reconstruction (ACLR) is often required as endogenous healing is limited and the stability provided by dynamic stabilisers is insufficient for complete joint function. A graft, comprising either biological tissue or synthetic material, is used to replicate the biomechanical and structural properties of the native ACL to restore function.

View Article and Find Full Text PDF

Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.

View Article and Find Full Text PDF

IO-202 is a humanized immunoglobulin G1 monoclonal antibody with high affinity and specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3), which is predominantly expressed in monocytes and monocytic blasts. IO-202 induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vitro and in patients with leukemia. Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML), and the phase 1b dose expansion data of IO-202 combined with AZA for the treatment of hypomethylating agent (HMA)-naïve CMML.

View Article and Find Full Text PDF

Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.

View Article and Find Full Text PDF